Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1999;34:491-495

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Risk Factors
Right arrow Other hypertension
Right arrow Other etiology

(Hypertension. 1999;34:491-495.)
© 1999 American Heart Association, Inc.


Scientific Contributions

Microalbuminuria and Transcapillary Albumin Leakage in Essential Hypertension

Roberto Pedrinelli; Giuseppe Penno; Giulia Dell'Omo; Simona Bandinelli; Davide Giorgi; Vitantonio Di Bello; Renzo Navalesi; Mario Mariani

From the Dipartimento Cardiotoracico (R.P., G.D., M.M.), Diabetologia (G.P., S.B., R.N.), Medicina Interna (D.G., V.D.), Universita' di Pisa, Italy.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Microalbuminuria (an increased urinary albumin excretion that is not detectable by the usual dipstick methods for macroproteinuria) predicts cardiovascular events in essential hypertensive patients. A possible reason for this behavior is that albumin leaks through exaggeratedly permeant glomeruli exposed to the damaging impact of subclinical atherogenesis. To evaluate this possibility, the transcapillary escape rate of albumin (TERalb, the 1-hour decline rate of intravenous 125I-albumin), a parameter that estimates the integrity of systemic capillary permeability, albuminuria, blood pressure, echocardiographic left ventricular mass, lipids, and body mass index were measured in 73 uncomplicated, glucose-tolerant men with essential hypertension and normal renal function; 53 were normoalbuminuric, and 20 were microalbuminuric. Twenty-one normotensive age-matched male subjects were the controls. TERalb was higher in hypertensives, a behavior explained in part by a positive correlation with blood pressure values, although body mass index, lipids, and left ventricular mass showed no association. Transcapillary albumin leakage values did not differ between normoalbuminuric and microalbuminuric patients and were unrelated to albuminuria. Blood pressure, particularly systolic, and cardiac mass were higher in microalbuminuric patients in whom albuminuria correlated with both cardiovascular variables and indicated the influence of the hemodynamic load on urinary albumin levels. Thus, TERalb, a parameter influenced by the permeability surface area product for macromolecules and the filtration power across the vascular wall, is altered in essential hypertensives. However, this abnormality is dissociated from the amount of albuminuria, which is contrary to the hypothesis that a higher albumin excretion reflects a greater degree of systemic microvascular damage in essential hypertension.


Key Words: albuminuria • hypertension, essential • cardiac mass • blood pressure • capillary permeability


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Microalbuminuria (ie, an abnormal urinary albumin excretion [UAE] in a range not detectable by the usual dipstick methods for urinary protein) is associated with a greater incidence of cardiovascular events in hypertensive patients1 2 3 and predicts all-cause and coronary disease morbidity and mortality independently from other cardiovascular risk factors in nondiabetic populations.4 5 6 7 However, the reasons why a renal parameter behaves as a marker of atherosclerotic cardiovascular disease in hypertension remain obscure. One concept postulates that more albumin leaks through exaggeratedly permeant glomeruli that reflect the systemic damaging impact of subclinical atherogenesis,8 a process characterized by a diffuse involvement of the entire vascular system.9 This hypothesis, which was originally formulated to account for the higher cardiovascular morbidity rate in diabetic patients,8 may also apply to essential hypertensive patients,10 but no information is available on this issue at this time.

To bridge the gap, we studied the behavior of the transcapillary escape rate of albumin (TERalb, the fraction of the intravascular mass of albumin passing through the vascular bed per unit time), a parameter determined by the permeability surface area product for macromolecules and the filtration power across the vascular wall and that estimates the integrity of the systemic capillary network.11 TERalb was evaluated in relation to UAE and other cardiovascular and metabolic variables in a group of uncomplicated essential hypertensive patients, who were or were not microalbuminuric.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Subjects
The hypertensive sample included 73 eligible stage 1 to 3 essential hypertensive male patients consecutively screened in our center. Eligibility required casual blood pressure (BP) values >140/90 mm Hg while on no treatment, normal oral glucose tolerance (2-hour post–oral glucose load <7.8 mmol/L [140 mg/dL]), serum creatinine <110 µmol/L (1.2 mg/dL), total serum cholesterol <7.8 mmol/L (300 mg/dL), normal urinary sediment, no urinary tract infection, body mass index (BMI) <30 kg/m2, and no evidence (ejection fraction >50%) or history of myocardial infarction, congestive heart failure, or cerebrovascular disease. Renal ultrasound scan showed normal-sized kidneys, although routine clinical and hematological examinations excluded other secondary forms of hypertension. No patient had ever been on lipid-lowering drugs. Fifty-one patients were newly diagnosed, and the remaining 22 patients were evaluated after a 4-week washout period. Twenty-one men with normal physical examination, routine blood and urinary tests, BP, ECG, abdominal echograms, and ankle/brachial index were the controls. Data collection was completed in 2 weeks.

According to institutional guidelines, subjects were aware of the investigational nature of the study and agreed to participate. The study was performed in accordance with the Declaration of Helsinki, and the protocol was approved by the local ethical committee.

Experimental Procedures
125I-labeled human serum albumin (6 to 8 µCi [222 to 296 kBq]; SARI-125 A-2, SORIN Biomedica) was bolus injected after the patient had a 30-minute rest in the sitting position, and blood was withdrawn from the contralateral arm every 5 minutes during the hour after the injection, as described.12 Radioactivity was measured (Cobra 5000 {gamma}-counter; Packard) in duplicate in whole blood samples centrifuged for 10 minutes at 3000g for 40 minutes. Hematocrit (Coulter Counter 55; Coulter Electronics) was determined in each sample by micromethod (intra-assay variation coefficient, 1.5±0.4%, SD) without any consistent change, which indicated a stable plasma volume throughout the 1-hour period of sampling. Baseline serum albumin was measured by immunonephelometry (Behring Laser Nephelometer System, Behring; intra-assay variation coefficient, 5.2%) immediately before tracer injection. 125I labeling was obtained by electrolytic technique, a procedure that does not alter the biological behavior of albumin in vivo.13 Radioiodinated tracer batches were eluted from free 125I through passage in Sephadex G 25 mol/L columns (Column PD-10; Pharmacia), a purification step that reduces free 125I content in the injected dose to <1%; repeatability studies had also shown a mean 8.3% intrasubject variation coefficient of TERalb determination.12

At variance with the original studies performed in the morning after overnight fasts,12 we decided for technical reasons to run these studies between 2 and 4 PM after the subjects underwent a 4-hour fast, with no tea, coffee, alcohol, or tobacco since early morning. The influence of this protocol modification was studied in 5 normal men (age, 28±3 years) in whom measurements were obtained in both experimental conditions at 1-week intervals. TERalb determinations averaged 7.6±0.8%/h in the early afternoon versus 5.6±0.6%/h in the morning sessions (P<0.03 by paired t test). The latter figure was comparable to our previous results obtained in normal controls studied under the same experimental conditions (5.16±1.09%/h).12

UAE was measured by nephelometry (Behring; limit of detection, 0.1 mg/dL; interassay variation coefficient, 3.5%) on overnight samples collected from 8 PM to 8 AM during 3 consecutive days.14 Wall thickness and chamber volumes were determined by monodimensional and bidimensional echocardiograms (Hewlett Packard Sonos 1000) with 2.5- and 3.5-MHz transducers.15 BP was measured through an automated oscillometric device (SpaceLabs 90207, SpaceLabs) every 8 minutes throughout a 2-hour interval during the TERalb procedure.

Anthropometric measurements (height and weight) were performed after each participant had removed his shoes and upper garments. Blood samples were obtained between 8 and 9 AM after an overnight fasting and 15 minutes of supine rest. Total cholesterol, HDL cholesterol, and triglycerides were assessed by enzymatic colorimetric techniques (Boehringer-Mannheim). Serum and urine creatinine levels were assayed by standard colorimetric methods.

Data Analysis
Plasma 125I-labeled albumin concentration (cpm/mL) was plotted on a semilogarithmic scale, and the transcapillary escape rate (%/h) was calculated from the monoexponential disappearance rate constant of the 125I curve from 10 to 60 minutes.12 Only linear regression values with a correlation coefficient of >=0.85 were accepted. UAE (µg/min) was the average of 3 consecutive overnight collections (median variation coefficient of the triplets, 22%; range, 0.5% to 127%). Microalbuminuria was defined as a value between 15 and 150 µg/min16 ; 2 patients with UAE of 162 and 190 µg/min were included in the analysis. BP values were the arithmetic mean of >=12 readings after artifact editing. Plasma volume (mL/1.73 m2) was determined by retropolation to zero time of the disappearance curve corrected for the injected dose of tracer obtained by weighing the syringes before and after the injection. BMI (body weight/squared surface area), creatinine clearance, and LDL cholesterol [total cholesterol-(HDL cholesterol+triglyceride/5)] were derived from standard formulas. Left ventricular mass (Penn convention) was corrected for body surface area to derive the left ventricular mass index (LVMI) (g/m2).

Statistical Analysis
Log transformation was applied to raw data not distributed normally. Descriptive statistics were expressed as mean±SD or median (range) for skewed data. Differences among means were tested by 1-way ANOVA, and a multiple range test was used to evaluate differences between means. Intraindividual association of variables was tested by Pearson's correlation coefficients. Statistical significance was set at P<0.05. Calculations were performed by the use of Statgraphics Plus (release 1997, Manugistic Inc).


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
UAE averaged 6 µg/min (range, 2 to 14 µg/min) in the controls (n=21). Of 73 hypertensives, 53 were normoalbuminuric (UAE, 7 µg/min [range, 2 to 15 µg/min]) and 20 were microalbuminuric (UAE, 26 µg/min [range, 15.3 to 190 µg/min]). Age, prevalence of current smokers, serum albumin, plasma volume, hematocrit, and total and fractionated cholesterol did not differ. Triglycerides and BMI were higher in patients (Table 1), irrespective of urine albumin levels.


View this table:
[in this window]
[in a new window]
 
Table 1. Age, Smoking Habits, Lipids, and BMI in Controls and Essential Hypertensive Patients Categorized According to UAE Levels

Transcapillary Escape Rate of Albumin
TERalb was higher (9.6±2.7%/h [n=73] versus 6.9±1.2%/h [n=21]; P<0.0001) in hypertensive patients than in normotensive controls. TERalb did not differ between normoalbuminuric and microalbuminuric patients (Figure 1).



View larger version (15K):
[in this window]
[in a new window]
 
Figure 1. Comparable TERalb between normoalbuminuric (n=53) and microalbuminuric (n=20) essential hypertensive patients. Data of age- and sex-matched controls are also reported (n=21). To provide more adequate information about data distribution, results are presented as box-and-whisker plots. The central box encloses the middle 50% of the data, the horizontal line inside the box represents the median, and the mean is plotted as a cross. Vertical lines (whiskers) extend from each end of the box and cover 4 interquartile ranges.

BP and Left Ventricular Mass
Thicker interventricular septum and posterior wall, superimposable end-diastolic diameter, and higher LVMI characterized patients from controls (Table 2). Systolic and, somewhat less consistently so (P<0.1), diastolic BP and LVMI were greater in microalbuminuric than in normoalbuminuric hypertensive subjects (Figure 2 and Table 2).


View this table:
[in this window]
[in a new window]
 
Table 2. BP and Cardiac Parameters in Controls and Essential Hypertensive Patients Categorized According to UAE Levels



View larger version (11K):
[in this window]
[in a new window]
 
Figure 2. Greater BP and LVMI (mean±SD) in essential hypertensives with microalbuminuria (n=20) vs normoalbuminuric patients (n=53). Data of age- and sex-matched controls are also reported (n=21). For statistics, see Table 2. SBP indicates systolic blood pressure; DBP, diastolic blood pressure.

Correlations
TERalb and UAE values were unrelated parameters (Figure 3), even when the 2 patient subgroups (normoalbuminuric patients: r=-0.06; n=53; microalbuminuric patients: r=-0.13; n=20) were analyzed separately. Among the continuous variables listed in Tables 1 and 2, only systolic (r=0.38, P<0.002; n=94) and, to a lesser extent, diastolic (r=0.22, P<0.03; n=94) BP correlated with TERalb. Higher UAE values were associated with more elevated BP (systolic: r=0.43, P<0.00001; diastolic: r=0.25, P<0.01; n=94) and LVMI (r=0.28, P<0.006; n=94).



View larger version (18K):
[in this window]
[in a new window]
 
Figure 3. Absence of a relationship between TERalb and UAE (log scale). The plot identifies control subjects ({diamondsuit}, n=21) and normoalbuminuric ({square}, n=53) and microalbuminuric (•, n=20) hypertensive patients. The correlation coefficient was 0.06; n=94.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Dissociation Between Albuminuria and Transcapillary Albumin Leakage
The lack of any association with TERalb, a parameter that estimates the integrity of systemic capillary permeability,11 does not support the view of an augmented urinary albumin leak as a marker a systemic microvascular disturbance in uncomplicated essential hypertensives. This negative conclusion is the same as that drawn from studying TERalb behavior in nondiabetic subjects, either normotensive or hypertensive, with fully developed atherosclerotic disease.17 On the other hand, the hemodynamic load appeared to be a more important determinant of albuminuria in this study as well as in previous studies of microalbuminuric patients characterized by higher BP (see Reference 1818 for a review) that, if transmitted to renal glomeruli, might increase glomerular ultrafiltration of albumin. However, this possibility, which is supported by results of clinical trials in which acute increments19 and decrements20 in systemic perfusion pressure caused consensual UAE changes, is not consistent with the renal hemodynamic pattern that emerged from studies in essential hypertensive subjects with microalbuminuria.21 Furthermore, accruing epidemiological evidence shows pressure-independent links between albuminuria and vascular disease.4 5 6 7 22 Thus, incompletely explored nonhemodynamic factors14 23 may contribute to increase UAE, even though exaggerated capillary permeability (present data and Reference 1717 ), accelerated Na+-H+ exchange rate,24 and hyperinsulinemia15 25 did not explain that phenomenon in essential hypertension in our previous experience.

It was important to be able to reproduce the TERalb values previously reported by us in normal subjects12 because this indicates the validity of the radioiodinated tracer. Therefore, nontechnical reasons, eg, circadian rhythms or accelerated lymph flow,26 may explain the slightly higher normal TERalb measured in the early afternoon after only 4 hours of abstinence from food. These considerations are to be remembered when our data are compared with those obtained by other investigators performing the technique under conditions of more prolonged fasting. Still, this discrepancy does not invalidate the present conclusions because the same strictly standardized protocol was applied to both patients and controls. It is also relevant to highlight the contrast between our data and those obtained in diabetes,11 12 27 a difference probably explained by the peculiar characteristics of that disease, as well as in acute infections28 and high altitude ascent,29 stressful conditions that differ markedly from stable, uncomplicated mild-moderate essential hypertension. Other, albeit somewhat more speculative, possibilities can also be hypothesized. Similar to the explanation put forward for the lack of differences in TERalb between patients with diabetic and incipient nephropathy,27 a ceiling may exist for the transcapillary albumin escape rate11 that hypertension per se might maximally accelerate, thus obscuring any further vascular leak associated with microalbuminuria. This hypothesis is supported by in vitro models that predict marked increases in macromolecular transport even when the capillary wall is only minimally altered,30 but the relevance of this model to the human situation is unknown. Type of previous antihypertensive medication31 or the length of treatment might have affected the transcapillary leakage of albumin, although this is an unlikely possibility because the majority of our patients had never been treated and the others were studied after an appropriate drug withdrawal period. It might even be speculated whether increased albuminuria in the presence of abnormal glomerular permselectivity might be obscured by compensation of other renal control mechanisms, such as modulation of afferent and efferent arteriolar tone, and mesangial cell contractility modifications that may change surface filtration area.32 Confounding from circadian variability in UAE might also play some role, because albuminuria and TERalb were measured at different times of the day, but our data cannot provide data in favor of or against any of the above possibilities. As a final point, ex post facto calculation of statistical power showed that our sample size (53 normoalbuminuric versus 20 microalbuminuric patients) had the statistical power to exclude safely (ß<0.20) differences in TERalb >=1.9%/h. Figures lower than that limit could not be identified safely, a limitation to be taken into account.

Transcapillary Albumin Leakage in Essential Hypertension
Our results confirm33 the influence of systemic BP levels, more the systolic than the diastolic component in this particular sample, on TERalb, a parameter influenced by the permeability surface area product for macromolecules and the filtration power across the vascular wall. Hypertension may increase capillary pressure,34 and acute elevation in systemic perfusion pressure may accelerate hyperfiltration,35 although other data are not consistent with this hypothesis.36 On the other hand, the correlation with BP did not explain the largest part of TERalb variability, which suggested the influence of additional factors on the abnormal vascular albumin permeation. Both larger surface capillary area in which most of the albumin exchange takes place,11 and plasma volume expansion37 might play a role, but the capillary network seems rarefied in hypertension,38 although plasma volume was normal in our patients. Increased permeability of vascular endothelium, perhaps in the context of the endothelial dysfunction described in some hypertensive patients,39 is also to be taken into account. However, it is impossible to be more specific because transcapillary macromolecular transport is a complex phenomenon, and hypertension might damage each of several different pathways, such as diffusion through endothelial cell membranes, passage via intercellular junctions, transendothelial channels of organs and tissues with highly different permeability, and surface area products.40

In conclusion, systemic capillary permeability is altered in essential hypertensives, but this abnormality is not reflected by proportionate changes in albuminuria, in contrast to the hypothesis that the augmented urinary albumin leak through the glomerular capillaries reflects a greater perturbation of systemic microvascular permeability in chronic essential hypertension.


*    Acknowledgments
 
This work was supported in part by a grant from CNR (Consiglio Nazionale delle Ricerche), Rome, Italy. We wish to thank Professor Romano Bianchi (Department of Oncology, University of Pisa) for his advice about albumin metabolism.


*    Footnotes
 
Reprint requests to Roberto Pedrinelli, MD, Dipartimento Cardiotoracico, Universita' di Pisa, Italy.

Received April 16, 1999; first decision May 7, 1999; accepted May 13, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 1996;14:223–228.[Medline] [Order article via Infotrieve]

2. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors: a population-based study of 1254 hypertensive individuals. J Hum Hypertens. 1997;11:727–732.[Medline] [Order article via Infotrieve]

3. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998;16:1325–1333.[Medline] [Order article via Infotrieve]

4. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet. 1988;2:530–533.[Medline] [Order article via Infotrieve]

5. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. BMJ. 1990;300:297–300.

6. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91:831–837.[Abstract/Free Full Text]

7. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects: the Insulin Resistance Atherosclerosis Study (IRAS). Stroke. 1997;28:1710–1716.[Abstract/Free Full Text]

8. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia.. 1989;32:219–226.[Medline] [Order article via Infotrieve]

9. Chobanian A. Overview: hypertension and atherosclerosis. Am Heart J. 1988;116(pt 2):319–322.

10. Pedrinelli R. Microalbuminuria in essential hypertension: a marker of systemic vascular damage? Nephrol Dial Transplant.1997;12:379–381.

11. Parving HH. Microvascular permeability to plasma proteins in hypertension and diabetes mellitus in man: on the pathogenesis of hypertensive and diabetic microangiopathy. Dan Med Bull. 1975;22:217–233.[Medline] [Order article via Infotrieve]

12. Nannipieri M, Pilo A, Rizzo L, Penno G, Rapuano A, Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care. 1995;18:1–9.[Abstract]

13. Rosa U, Pennisi F, Bianchi R, Federighi G, Donato L. Chemical and biological effects of iodination on human albumin. Biochim Biophys Acta. 1967;133:486–498.[Medline] [Order article via Infotrieve]

14. Pedrinelli R, Giampietro O, Carmassi O, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F, Di Bello V. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18.[Medline] [Order article via Infotrieve]

15. Pedrinelli R, Bello VD, Catapano G, Talarico L, Materazzi F, Santoro G, Giusti C, Mosca F, Melillo E, Ferrari M. Microalbuminuria is a marker of left ventricular hypertrophy but not hyperinsulinemia in nondiabetic atherosclerotic patients. Arterioscler Thromb. 1993;13:900–906.[Abstract/Free Full Text]

16. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Jensen G, for the Copenhagen City Heart Study Group. Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects. Scand J Clin Lab Invest. 1993;53:867–872.[Medline] [Order article via Infotrieve]

17. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, Nannipieri M, Navalesi R, Mariani M. Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. Hypertension. 1998;32:312–318.

18. Pedrinelli R. Microalbuminuria in hypertension. Nephron. 1996;73:499–505.[Medline] [Order article via Infotrieve]

19. Hoogenberg K, Sluiter WJ, Navis G, Van Haeften TW, Smit AJ, Reitsma WD, Dullaart RP. Exogenous norepinephrine induces an enhanced microproteinuric response in microalbuminuric insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1998;9:643–654.[Abstract]

20. Christensen CK. Rapidly reversible albumin and beta2-microglobulin hyperexcretion in recent severe essential hypertension. J Hypertens. 1983;1:45–51.[Medline] [Order article via Infotrieve]

21. Mimran A, Ribstein J, DuCailar G. Is microalbuminuria a marker of early intravascular damage in essential hypertension? Hypertension.. 1994;23:878–883.[Abstract/Free Full Text]

22. Pedrinelli R, Lindpaintner K, Dell'Omo G, Napoli V, Di Bello V, De Caterina R, Petrucci R. Urinary albumin excretion and atherosclerosis in essential hypertension. Clin Sci (Colch). 1997;92:45–50.[Medline] [Order article via Infotrieve]

23. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM, Donker AJM, Stehouwer CDA. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int. 1998;54:203–209.[Medline] [Order article via Infotrieve]

24. Giampietro O, Matteucci EG, Catapano G, Dell' Omo G, Talarico L, Di Bello V, Pedrinelli R. Microalbuminuria and erythrocyte Na+/H+ exchange in hypertension: hemodynamic and metabolic correlates. Hypertension. 1995;25:981–985.[Abstract/Free Full Text]

25. Pedrinelli R, Dell'Omo G, Giampietro O, Giorgi D, Di Bello V, Bandinelli S, Penno G, Mariani M. Dissociation between albuminuria and insulinemia in hypertensive and atherosclerotic men. J Hum Hypertens. 1999;13:129–134.[Medline] [Order article via Infotrieve]

26. Bianchi R, Mariani G, Pilo A, Toni MG. Albumin distribution from short-term tracer studies in man. In: Bianchi R, Mariani G, McFarlane AS, eds. Plasma Protein Turnover. Baltimore, Md: University Park Press; 1976:71–84.

27. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1986;29:282–286.[Medline] [Order article via Infotrieve]

28. Davis TM, Suputtamongkol Y, Spencer JL, Ford S, Chienkul N, Schulenburg WE, White NJ. Measures of capillary permeability in acute falciparum malaria: relation to severity of infection and treatment. Clin Infect Dis. 1992;15:256–266.[Medline] [Order article via Infotrieve]

29. Hansen JM, Olsen NV, Feldt-Rasmussen B, Kanstrup IL, Dechaux M, Dubray C, Richalet JP. Albuminuria and overall capillary permeability of albumin in acute altitude hypoxia. J Appl Physiol. 1994;76:1922–1927.[Abstract/Free Full Text]

30. Nir A, Pfeffer R. Transport of macromolecules across arterial wall in the presence of local endothelial injury. J Theor Biol. 1979;81:685–711.[Medline] [Order article via Infotrieve]

31. Nielsen FS, Rossing P, Gall MA, Smidt UM, Chen JW, Sato A, Parving HH. Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand J Clin Lab Invest. 1997;57:427–434.[Medline] [Order article via Infotrieve]

32. Anderson S, Garcia DL, Brenner BM. Renal and systemic manifestations of glomerular disease. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia, Pa: WB Saunders; 1991:1831–1843.

33. Parving HH, Gyntelberg F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circ Res. 1973;32:643–651.[Abstract/Free Full Text]

34. Williams SA, Boolell M, MacGregor GA, Smaje LH, Wasserman SM, Tooke JE. Capillary hypertension and abnormal pressure dynamics in patients with essential hypertension. Clin Sci. 1990;79:5–8.[Medline] [Order article via Infotrieve]

35. Parving HH, Nielsen SL, Lassen NA. Increased transcapillary escape rate of albumin, IgG, and IgM during angiotensin-II–induced hypertension in man. Scand J Clin Lab Invest. 1974;34:111–118.[Medline] [Order article via Infotrieve]

36. Shore AC, Sandeman DD, Tooke JE. Effect of an increase in systemic blood pressure on nailfold capillary pressure in humans. Am J Physiol. 1993;265:H820–H823.[Abstract/Free Full Text]

37. Parving HH, Rossing N, Nielsen SL, Lassen NA. Increased transcapillary escape rate of albumin, IgG, and IgM after plasma volume expansion. Am J Physiol. 1974;227:245–250.

38. Prasad A, Dunnill GS, Mortimer PS, MacGregor GA. Capillary rarefaction in the forearm skin in essential hypertension. J Hypertens. 1995;13:265–268.[Medline] [Order article via Infotrieve]

39. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 1997;39:287–324.[Medline] [Order article via Infotrieve]

40. Hinsbergh VWM. Endothelial permeability for macromolecules: mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol. 1997;17:1018–1023.[Free Full Text]




This article has been cited by other articles:


Home page
Diabetes CareHome page
A. J.M. Rennings, P. Smits, M. W. Stewart, and C. J. Tack
Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
Diabetes Care, March 1, 2006; 29(3): 581 - 587.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. L. Hillege, V. Fidler, G. F.H. Diercks, W. H. van Gilst, D. de Zeeuw, D. J. van Veldhuisen, R. O.B. Gans, W. M.T. Janssen, D. E. Grobbee, P. E. de Jong, et al.
Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population
Circulation, October 1, 2002; 106(14): 1777 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. Pedrinelli, G. Dell'Omo, G. Penno, and M. Mariani
Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease
Vascular Medicine, November 1, 2001; 6(4): 257 - 264.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. DeMaio, Y. S. Chang, T. W. Gardner, J. M. Tarbell, and D. A. Antonetti
Shear stress regulates occludin content and phosphorylation
Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H105 - H113.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedrinelli, R.
Right arrow Articles by Mariani, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Risk Factors
Right arrow Other hypertension
Right arrow Other etiology